Predicting durable remissions following thalidomide therapy for relapsed myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• The correlation between response depth and survival outcomes in multiple myeloma (MM) is not fully established.
• Relapsed or refractory MM poses a significant clinical challenge, necessitating research into factors influencing treatment efficacy.

Purpose of the Study:

• To evaluate the long-term impact of response depth on progression-free survival (PFS) and overall survival (OS) in relapsed or refractory MM.
• To identify baseline predictors of durable response in MM patients treated with thalidomide-based regimens.

Main Methods:

• Updated long-term follow-up data from two multi-center phase-II trials involving 141 relapsed/refractory MM patients.
• Analysis of PFS and OS based on achieved response levels (complete remission, very good partial remission, partial remission, stable disease).
• Assessment of baseline serum beta(2)-microglobulin as a predictor of durable PFS and OS.

Main Results:

• Nineteen percent (27/141) of patients achieved PFS beyond 24 months.
• Serum beta(2)-microglobulin <= 3.0 mg/L was the strongest baseline predictor for durable PFS and OS.
• Median PFS: 69.4 months (CR/VGPR), 13.6 months (PR), 4.1 months (SD) (p < 0.001).
• Median OS: >69.8 months (CR/VGPR), 35.4 months (PR), 11.7 months (SD) (p < 0.001).

Conclusions:

• Achieving maximum depth of response is a critical therapeutic goal in relapsed multiple myeloma.
• Depth of response is a significant determinant of long-term PFS and OS in MM.
• Baseline serum beta(2)-microglobulin level is a valuable prognostic marker for MM patients.